The Week in Review in Drug Pricing

TL;DR of PhRMA's statement on the House plan to lower drug prices? "We're good with the high prices, thanks."

Welcome to the Week in Review in prescription drug pricing!

1.Get on board the negotiation train

  • The House has offered up a robust plan that would allow Medicare to negotiate prescription drug prices. It would lead to major savings for patients and taxpayers across America. — (AP)

2.Patients over party!

  • Trump Tweeted that he likes House Speaker Nancy Pelosi’s drug pricing plan and called for getting it done ‘the bipartisan way.’ Congress: Please do! — (STAT)


  • PhRMA and BIO are threatening the end of days if taxpayers negotiate. MEMO: The profit margins of drug corporations are almost three times the average of the S&P 500. Plenty of room to lower drug prices and fund innovation there. — (HealthLeaders Media)

4.Product hops must stop!

  • A patient and an academic gave this insidious Big Pharma tactic the what for at a House Congressional hearing. What’s it all mean? — (P4AD & Regulatory Focus)

5.International Pricing Index: Let’s make a deal

  • Everybody loves the International Pricing Index! (Except for pharma, but nobody likes them). — (NPR)